# Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer

> **NCT00321893** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 225 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Budesonide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00321893
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2016-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321893, "Budesonide in Treating Patients With Lung Nodules at High Risk of Developing Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00321893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*